



**23-FEB-2019 6:10  
CANCER CONTROL ACCRUAL REPORT**

STUDY	O R P E E G N	ARM	REGS.						ADMIN
			TOTAL REGS.	LAST Month	LAST Month	LAST Month	LAST DAYS	LAST DAYS	
			0	0	0	0	0	0	
S1602-Blad, HG NMIBC, TICE/Tokyo/Prime+Tokyo BCG	1 Y 1	TICE BCG	80	55	30	17	6	1	GU
	2	Tokyo-172 BCG	79	55	31	16	5	0	
	3	Prime + Tokyo-172 BCG	78	55	31	16	5	2	
			<u>237</u>	<u>165</u>	<u>92</u>	<u>49</u>	<u>16</u>	<u>3</u>	
S1614-HBV in Ca Pts, TAF vs SOC	1 Y		0	0	0	0	0	0	SXQOL
			<u>0</u>	<u>0</u>	<u>0</u>	<u>0</u>	<u>0</u>	<u>0</u>	
S1703-Met Breast, STM-monitoring v Usual Care	1 Y 0	Screening	26	26	26	20	13	1	CCD
			<u>26</u>	<u>26</u>	<u>26</u>	<u>20</u>	<u>13</u>	<u>1</u>	
	2 Y 1	Control (Usual Care)	1	1	1	0	0	0	
	2	Intervention (STMDDM)	1	1	1	0	0	0	
			<u>2</u>	<u>2</u>	<u>2</u>	<u>0</u>	<u>0</u>	<u>0</u>	
S1802-Pros, Stg IV, SST +/- Surg/RT to Primary Tum	1 Y 0	Induction SST	35	35	35	17	6	1	GU
			<u>35</u>	<u>35</u>	<u>35</u>	<u>17</u>	<u>6</u>	<u>1</u>	
	2 Y 1	Standard Systemic Therapy Only	5	5	5	2	1	0	
	2	SST + Surgery/RT	6	6	6	2	1	0	
			<u>11</u>	<u>11</u>	<u>11</u>	<u>4</u>	<u>2</u>	<u>0</u>	
S0820-PACES: ColrecStg0-3 Blind DFMO/Sulindac	0 Y 0	Pre-Registration	520	48	21	13	3	2	PREV
			<u>520</u>	<u>48</u>	<u>21</u>	<u>13</u>	<u>3</u>	<u>2</u>	
	1 Y 1	Blinded drug	81	25	13	8	2	1	
	2	Blinded drug	36	0	0	0	0	0	
	3	Blinded drug	35	0	0	0	0	0	
	4	Blinded drug	79	20	8	5	1	0	
			<u>231</u>	<u>45</u>	<u>21</u>	<u>13</u>	<u>3</u>	<u>1</u>	

**23-FEB-2019 6:10**  
**CANCER CONTROL ACCRUAL REPORT**

06:10 Saturday, February 23, 2019 3

Open Studies with No Registrations

---

S1600-Bladder,Radical Cystectomy Outcomes Nutrition regtype: 1

S1614-HBV in Ca Pts, TAF vs SOC regtype: 1